We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Targets Approval-Delaying Petitions in Final Guidance
FDA Targets Approval-Delaying Petitions in Final Guidance
The FDA features the misuse of petitions to stall generic drug applications in a final guidance issued Wednesday — and spells out how the agency will deal with the petitions.